
usd pm et
summari second largest distributor pharmaceut broad rang
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
revenu fy sept grew
reflect broad demand growth specialti
biolog rise conventino drug volum
largest custom walgreen
express script combin roughli
revenu persist declin
 fy pharmaceut
distribut oper margin flat yoy
coincid view
multi-year gener price deflat headwind
also think margin benefit reduc
cost rapidli grow biolog
distribut busi gener
expens convent drug distribut
revenu improv fy
outpac revenu growth four
expect keep oper margin stabl
fy think gener deflat
mostli off-set improv distribut
init parternship see
much room margin improv howev
consolid trend among larg
custom give greater bargain
power come distribut fee
estim fy sep yield
combin
outlook modest long-term growth like
give share attract upsid expect
firm grow annual oper earn
mid-singl digit long term age
strong pet ownership trend drive demand
growth convent drug specialti drug
veterinarian distribut servic
rise volum main driver
long-term earn growth view
trend integr among health care
provid insur pharmaci benefit
manag pbm increas scale
custom tend limit price gain
margin expans risk view
largest sharehold walgreen
stake competitor
target fy ep forecast --
histor forward price-to-earnings averag due
litig risk view limit
negoti power key custom
expect share repurchas significantli
contribut ep growth futur year
see strong long-term growth prospect drug
distributor volum age develop popul
expand health care coverag emerg market
drive prescript demand also see high barrier
entri due larg capit requir concentr
custom base three largest distributor hold
market share posit balanc
opioid litig risk view limit abil
rais price current environ distribut
fee often tie drug price view
current pressur due custom consolid
polit pressur
jan ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview amerisourcebergen corpor second largest pharmaceut
distribut compani primari busi entail wareh logist servic
connect manufactur brand-nam gener pharmaceut end-us outlet downstream
custom includ wide varieti retail mail-ord pharmaci hospit network outpati
facil long-term care facil veterinarian practic also offer value-ad servic
manufactur group purchas servic physician practic
occupi strong posit convent specialti pharmaceut distribut typic
inject infus drug particular strength oncology-rel servic specialti busi
histor achiev higher gross margin faster organ growth convent drug
distribut busi view due strong demand growth biolog drug develop improv
treatment larg patient therapeut area like cancer auto-immun inflammatori diseas
howev higher cost store transport specialti drug cost includ gross
profit typic result lower overal oper margin convent drug like pill
custom concentr import awar ten largest account total
revenu fy sep sale two largest custom
script esrx account revenu respect
market profil return wareh logist inventori data servic drug distribut
contract typic run multi-year period pay distributor negoti percentag purchas
order amount actual drug price usual negoti manufactur pharmaci
distributor actual drug price negoti result revenu fluctuat extern
drug price trend rise drug price typic lead greater fee revenu distributor drug price
inflat also help distributor tradit resal arrang sometim use
purchas bulk inventori manufactur resel downstream custom gain spread
increas lower-cost exist inventori sold new higher price
increas access health insur especi global middl class expand age develop
market popul posit long-term driver pharmaceut volum view drug
price critic factor profit recent year low price inflat brand drug
gener deflat result lower distribut fee negat posit impact higher volum
distributor see shrink profit margin drug inflat keep pace rise
big pharmaceut distributor
form gener drug sourc joint ventur jv larg retail pharmaci began
collabor jv improv bargain power gener manufactur
similar jv walgreen respect three jv repres
three largest pharmaceut distributor retail pharmaci chain
increas bargain power jv manufactur like factor gener price
deflat trend last sever year contribut slower sale growth convent
pharmaceut turn led distributor seek faster growth non-tradit drug busi
specialti pharmaceut medic suppli
corpor strategi focus expand convent specialti pharmaceut
distribut busi recent expans busi includ pharmedium
lead provid specialti product acut care hospit acquir novemb
januari acquisit smith formerli largest privat held drug
distributor
also enter strateg relationship wherebi
becam primari distribut resourc intern pharmaci compani return
grant warrant purchas stake gradual increas ownership roughli
novemb sinc launch relationship fy revenu growth materi exceed
competitor fy particularli activ driven addit
distribut busi see potenti risk move forward howev independ pharmaci
may ultim steer busi away avoid send profit larg competitor
competit landscap price breadth product offer value-ad servic program
primari competit factor drug distribut industri big domin larg
multi-year contract consolid amongst downstream custom major impact
distributor earn case gain busi
pharmaci chain sold store prior transact rival provid
distribut servic store
financi trend fy achiev three-year compound annual growth rate
revenu adjust earn per share adjust pre-tax incom margin fy
fy per share earn growth aid roughli billion net share buyback
fy view balanc sheet strong cash billion septemb
ebita-to-interest coverag
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
figur base fiscal year-end price
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
bullish sinc octob technic indic
bullish
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next year
neutral driven mix posit
neg factor posit side see
distribut revenu bolster growth
prescript volum slowdown brand
drug patent expir neg side
expect profit margin see continu
pressur consolid drug suppli
chain focu mainli drug
distribut busi gener
sub-industri revenu
prescript drug demand continu
increas turn drive
greater volum handl distributor
driven view age
babi boomer prime util year
gain health-insur popul
accord latest censu data
age cohort grow five time fast
total popul expect age
drive long-term growth prescript drug
demand senior tend health care
need younger cohort
addit recent censu data
indic health-insur
popul continu grow million
individu ad health plan
view peopl health insur
like prescript written fill
uninsur due manag
cost doctor visit drug insur
expect growth health-insur
popul continu year ahead
strong labor market especi
full-tim employ pull peopl onto
employ growth averag first
eight month line
job growth experienc
moreov full-tim job growth
outpac part-tim job growth bp
along rise prescript volum
distributor tend benefit higher
price brand drug gener
expect brand support favor
period low patent expir year
ahead data evaluatepharma indic
annual global drug sale risk expir
patent averag total
clear way substanti
amount lower-pr gener enter
market expir forecast drop
howev
posit brand drive
higher revenu distributor
typic collect percentag drug price
exchang manufactur
pharmaci exchang wareh
ship data track servic yet
longer term think brand drug price
face risk new regul politician
increasingli focus control voter
drug cost see outlook
immedi concern distributor
view grow scale
player drug suppli chain
consolid drug maker upstream
well pbm manag care firm
provid downstream on-going
negoti power supplier
custom distributor limit
abil improv oper margin
declin
year-to-d septemb
distributor index rose
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra maintain buy recommend share
amerisourcebergen corpor keep target
fy sep ep forecast rais fy ep estim
fy sep-q adjust ep vs
yoy beat consensu sep-q sale grew yoy steadi rise
volum standard drug strong growth specialti particularli
immuno-oncolog treatment see healthi demand environ continu
expect revenu grow oper incom grow
slower revenu though due lower margin specialti drug becom
larger share revenu also expect around free cash flow
market cap signific amount think go
share repurchas help deliv fy adjust ep growth line
revenu around opioid litig uncertainti like remain
next year think risk adequ price price-to-earnings valuat
histor averag /colin scarola
pm et cfra keep hold recommend share
corpor keep target fy
sept ep forecast -- histor forward price-to-earnings averag due view
negoti power custom diminish rais fy ep
estim keep mar-q ep vs
beat consensu mar-q revenu grew yoy higher drug volum
especi strong demand specialti drug adjust gross margin fell basi
point yoy quarter solid sg expens contain allow
stabl overal oper margin consist mar-q adjust
pre-tax incom per share grew yoy materi faster revenu
prolif share repurchas last year provid percentag point boost
stabil margin welcom develop contract throughout
see limit abil expand due downstream
consolid drug suppli chain improv custom purchas power
et cfra see investor sentiment improv defend
nation opioid case key bellweth trial opioid
epidem schedul begin monday intent presid judg
bring side comprehens settlement resolv relat
case nationwid trial approach see flurri report
settlement negoti includ news week big drug
distributor propos cap total liabil pay
year produc teva offer settlement worth
respect earli know coalit
state attorney lead negoti behalf plaintiff stand
offer see defend willing settl posit news opioid
litig uncertainti gener cost defend market valu via
neg sentiment like cost settl view move
toward settlement even costli one defend see share rise
uncertainti allevi /colin scarola
et cfra keep hold recommend share
corpor rais target fy
sept ep forecast -- histor forward price-to-earnings averag due
margin pressur expect lower fy ep estim
dec-q ep vs met
estim report solid revenu growth yoy dec-q although
estim organ growth roughli half exclud major
acquisit despit strong sale growth quarter
full year howev adjust pre-tax incom continu declin
drop yoy dec-q main culprit shrink margin
adjust gross margin cy cy think
stabil earn move past regulatori closur
pharmedium plant see limit growth ahead
consolid amongst upstream drugmak downstream payer like
continu pressur margin side /colin scarola
pm et cfra lift opinion share amerisourcebergen corpor
buy hold lift target fy
sep ep forecast -- histor forward price-to-earnings averag due
litig risk prolong headwind expect gener deflat
keep fy ep estim lift fy
initi fy gener deflat drove signific margin
compress manag stabil oper margin yoy
expect continu gener deflat think
off-set growth specialti drug companion anim distribut think
grow oper earn mid-singl digit long-term
age babi boomer rapid biolog drug develop strong pet ownership
trend drive demand growth tradit drug specialti drug companion
anim distribut respect estim fy yield
current market cap combin long-term growth outlook make
attract entri point /colin scarola
pm et cfra keep hold recommend share
corpor lift target fy
sep ep forecast -- histor forward price-to-earnings averag due
materi litig risk rais fy ep estim
jun-q ep vs yoy beat consensu
jun-q revenu grew yoy strong demand specialti
pharmaceut adjust oper margin held firm yoy second quarter
row posit sign much
character compress margin driven sever gener drug price
deflat adjust pre-tax incom per share yoy
materi outpac revenu growth appli debt
reduct share repurchas boost per share earn see
limit abil expand margin due downstream consolid
drug suppli chain improv custom purchas power expect ep
grow modestli steadi sale growth /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
